


Alliance for Biosecurity



The Alliance for Biosecurity's core mission is to partner with government, biopharma industry, and other stakeholders to advance the shared goal of developing critically needed medical countermeasures (MCMs) as quickly as possible, as well as enhancing funding for MCM development and advocate for other legal, regulatory and policy improvements to support the industry's efforts in MCM development

Key Activities and Priorities

The Alliance is the leading industry voice on biosecurity issues and is an efficient, strategic organization aimed at:

- ◆ Educating members of Congress and other government stakeholders about biosecurity and drug development issues
- ◆ Advocating for Congressional funding for biosecurity programs
- ◆ Developing and presenting industry consensus proposals to government on good biodefense policy
- ◆ Promoting the goals of the Biodefense Advanced Research and Development Authority (BARDA)
- ◆ Promoting constructive public-private collaborations on animal model and other scientific issues central to MCM development
- ◆ Providing a regular venue for industry dialogue and benchmarking on key biosecurity issues
- ◆ Facilitating mutually beneficial and constructive relationships and partnerships with stakeholders on biodefense issues

Recent Deliverables and Impact

During 2010, the Alliance continued to be highly influential on key issues relevant to biosecurity and development of MCMs, including:

- ◆ Effectively engaged in the HHS "end to end review" of the MCM enterprise; several of the Alliance's recommendations were incorporated in the August 2010 HHS Report on the Review
 - Met with high-level US officials, including Assistant Secretary for Preparedness, Dr. Nicole Lurie, and prepared white paper on review
- ◆ Advocated to preserve the Bioshield Special Reserve Fund (SRF) – critical source of funding for MCM development and procurement – and successfully advocated against at least 3 proposed Congressional "raids" (up to \$2 billion) of the SRF
- ◆ Testified before key Congressional Committees to advance biosecurity policy and secure adequate funding for development and procurement of MCMs
- ◆ Constructively engaged with FDA on critical policy/regulatory issues related to development of MCMs, including animal models

Membership

Benefits of Membership

The Alliance is an extremely credible and influential stakeholder and has successfully engaged key government officials on biosecurity issues to promote increased funding and better policies:

- ◆ United voice is stronger than individual, potentially diverging messages
- ◆ Legislators and policymakers often are more comfortable engaging with a group of companies
- ◆ Effective teaming with other organizations (e.g., BIO, Trust for America's Health, WMD Center)

Biodefense is a complex area with numerous government agencies/stakeholders and frequently opaque processes. The Alliance provides a facilitated opportunity for industry colleagues to appropriately share information, experiences, and best practices. In addition, the Alliance can help companies reduce costs of monitoring and advocacy efforts.

Membership Details

- ◆ Membership entitles each company to two seats on the Board (one primary and one alternate) and representation on any and all of the Working Groups.
- ◆ The Alliance Board of Directors meets regularly to discuss the status and evolution of the MCM sector, identifying and surfacing issues and opportunities of mutual importance to member companies, and frequently invites key government officials at ASPR, BARDA, FDA, and other key agencies to join its meetings.
- ◆ The Working Groups and Subteams meet by teleconference on a regular basis.
- ◆ 2011 Membership fees: capped at \$2300. per company per month.

Current Members:

Contact for Membership

Maureen Donahue Hardwick
Secretariat and Legal Counsel
email: maureen.hardwick@dbr.com
Phone: (202) 230-5133

Bavarian Nordic
Cangene Corporation
Elusys Therapeutics, Inc.
Emergent BioSolutions
Human Genome Sciences, Inc.
Pfizer Inc.
PharmAthene
SIGA Technologies
Unither Virology LLC,
a subsidiary of United Therapeutics